A public research surface · updated continuously
The drug supply chain will be won by whoever owns the chokepoints.
GLP-1 fill-finish, elastomer stoppers, bioprocessing resins, API reshoring, sterile injectables. Pharma Bottlenecks maps the manufacturing chain behind every blockbuster — not the molecules, the plants — and the listed companies that own each choke. Own the strait, not the tanker.
45 names tracked · 10 chokepoints · free, no login
The chokepoints
I
Sterile fill-finish capacity
GLP-1 demand turned aseptic fill-finish lines into the scarcest asset in pharma; capacity books out years ahead.
TMO · LLY · NVO · LZAGY · FUJIY · SIMTRA
II
Stoppers, syringes & drug-contact components
Every injectable passes through elastomer stoppers and glass barrels from two or three qualified suppliers — West's near-monopoly is the textbook choke.
WST · STVN · ATR · DTG.SW · GRRMY · YPHDF · SHLMEDICAL
III
Pharmaceutical glass & vials
Borosilicate vial and cartridge capacity concentrates in three companies; every injectable ramp strains it.
STVN · SHTPY · GLW · GRRMF · NPEGF
IV
Bioprocessing consumables & resins
Biologics manufacturing runs on single-use bags, filters and protein-A resin from an oligopoly with razor-blade economics.
RGEN · DHR · SDMHF · MKKGY · TMO · SOAGY
V
API & small-molecule reshoring
Most US generic APIs route through China and India; BIOSECURE-era reshoring is funded, dated, and capacity-constrained.
LZAGY · TMO · HKMPY · RDY · AMRX · SGFEF · WUXAY · USANTIBIOTICS
VI
CDMO capacity & the China exodus
WuXi handles a huge share of Western pipelines; every BIOSECURE headline reprices the non-Chinese CDMO bench.
LZAGY · TMO · WUXAY · WXIBF · FUJIY · CRL · SAMSUNGBIOLOGICS
VII
Peptide & oligonucleotide manufacturing
GLP-1s are peptides and the new genetic medicines are oligos — both need specialized synthesis capacity that is genuinely scarce.
BCHMY · LZAGY · A · MRVI · CORDENPHARMA
VIII
Sterile injectables & shortage economics
Chronic shortages in generic sterile injectables are a structural underinvestment story with FDA shortage lists as the public catalyst tape.
BAX · ICUI · AMRX · AMPH · HKMPY · FSNUY · VTRS
IX
Analytical instruments & QC release
Every batch released passes through chromatography, mass spec and sterility testing from a small instrument oligopoly.
WAT · A · MTD · TMO · DHR · CRL · BMXMF
X
Private giants & exposure vehicles
Catalent-under-Novo, Samsung Biologics, PolyPeptide, SHL — the manufacturing cap tables without US tickers, and the listed paths in.
WST · DAIKYOSEIKO · STVN · LZAGY · PLYGF · SGFEF · DTG.SW · NVO
Latest brief · 2026-10-23
Pharma was the defensive winner of the day's rotation — the fill-finish and bioprocessing chokepoint caught a flight-to-safety bid led by Sartorius — while Corning, now effectively an AI-optical-fiber stock, fell 8% with the tech tape.
The leader was Sartorius AG's ADR (SOAGY), up 4.9% to $61.56 on the bioprocessing chokepoint — the single-use bioreactors, filtration and chromatography media that gate biologics manufacturing. The gain was defensive rotation, not an earnings event: Sartorius has not yet posted Q3 results, and on Thursday's sharp risk-off tape — the Nasdaq Composite −2.60% to 26,008.86 against a Dow up 0.02% — money moved out of high-beta AI names and into steady healthcare-tools cash flows. Its Stedim subsidiary (SDMHF) rose 2.0% to $239.00 and CDMO peer Lonza (LZAGY) added 1.9% to $76.76, confirming the move was a sector bid rather than a one-name story.
The laggard was Corning (GLW), down 8.1% to $123.99. Corning's relevance to this vertical is the Valor pharmaceutical-glass chokepoint — the fracture-resistant vials that regulators and fillers increasingly specify — but its stock now trades largely on its optical-fiber franchise, which has become a core AI-datacenter supplier. On a day the AI-infrastructure complex was routed, that exposure dominated: Corning fell with the tech tape, not on any pharma news (it reports Q3 later this month). The broader life-science-tools rung, the vertical's other high-beta corner, softened with it — Maravai (MRVI) −6.6% to $7.07 on reagents, WuXi AppTec's ADR (WUXAY) −3.8% to $23.92, Thermo Fisher (TMO) −2.5% to $676.54, Agilent (A) −2.2% to $173.89 and Danaher (DHR) −1.8% to $229.75.
The rest of the fill-finish and delivery rung — the physical chokepoint between a drug substance and a usable dose — was the day's safe harbor. ICU Medical (ICUI) rose 4.7% to $168.33 and Baxter (BAX) 3.8% to $25.65 on infusion hardware, while the containment names held firm: Stevanato (STVN) +3.6% to $19.50 on glass and ready-to-use cartridges, Aptar (ATR) +2.0% to $128.10 on drug-delivery devices, and West Pharmaceutical (WST) roughly flat at +0.1% to $394.03. West's steadiness came on its own print — it reported Q3 results Thursday, the vertical's one dated catalyst of the session — and Eli Lilly (LLY), the demand engine behind the GLP-1 fill-finish crunch, rose 2.8% to $1,306.69.
The near calendar is policy-heavy. Charles River reports Q3 on November 5, and the statutory BIOSECURE deadline for OMB to publish its initial list of "biotechnology companies of concern" falls December 18 — the date that most directly reprices the Western-CDMO-versus-WuXi supply question this vertical maps. Stevanato's Fishers, Indiana and Latina, Italy ready-to-use cartridge lines are targeted for commercial start around the turn of the year, the capacity response to the delivery bottleneck. With the Section 232 pharmaceutical tariffs already in force since July, the onshoring of the fill-finish chokepoint, not daily tape swings, remains the structural story.